The Zhitong Finance App learned that Guoyuan International released a research report saying that it gave Shiyao Group (01093.HK) a “buy” rating, with a target price of HK$10.11. The company actively lays out innovative drugs, has increased investment in R&D, and has continued to invest heavily in R&D. It has built an international pipeline and leading platform, and has achieved remarkable overseas results. Although the proprietary drug business was pressured by collection in the short term, single-quarter results have shown a steady upward trend, and many core innovative drugs are nearing key points, and authorized revenue has become a new growth point, laying a solid foundation for medium- to long-term growth.

The Zhitong Finance App learned that Guoyuan International released a research report saying that it gave Shiyao Group (01093.HK) a “buy” rating, with a target price of HK$10.11. The company actively lays out innovative drugs, has increased investment in R&D, and has continued to invest heavily in R&D. It has built an international pipeline and leading platform, and has achieved remarkable overseas results. Although the proprietary drug business was pressured by collection in the short term, single-quarter results have shown a steady upward trend, and many core innovative drugs are nearing key points, and authorized revenue has become a new growth point, laying a solid foundation for medium- to long-term growth.